Skip to main content

Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro.

  • 2012-06
  • International Journal of Food Microbiology 157(1)
    • R. Pérez-Torrado
    • S. Llopis
    • L. Jespersen
    • Teresa Fernández-Espinar
    • A. Querol

Abstract

Saccharomyces cerevisiae is generally considered to be a safe organism and is essential to produce many different kinds of foods as well as being widely used as a dietary supplement. However, several isolates, which are genetically related to brewing and baking yeasts, have shown virulent traits, being able to produce human infections in immunodeficient patients. Previously it has been shown that the administration of S. cerevisiae clinical isolates can lead to systemic infections, reaching several organs in murine systems. In this work, we studied S. cerevisiae clinical isolates in an in vitro intestinal epithelial barrier model, comparing their behaviour with that of several strains of the related pathogens Candida glabrata and Candida albicans. The results showed that, in contrast to C. glabrata and C. albicans, S. cerevisiae was not able to cross the intestinal barrier. We concluded that S. cerevisiae can only perform opportunistic or passive crossings when epithelial barrier integrity is previously compromised.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Saccharomyces cerevisiaeImpaired Intestinal Barrier FunctionNeutral
Moderate
Saccharomyces cerevisiaeIncreased Risk of Opportunistic Infection due to Compromised Epithelial BarrierHarmful
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.